FDAnews Drug Daily Bulletin
Pharmaceuticals / Submissions and Approvals

Soricimed’s Ovarian Cancer Therapy Secures Orphan Drug Status

March 15, 2016
A A

Canadian drugmaker Soricimed Biopharma has secured orphan drug designation for its peptide SOR-C13 for treatment of ovarian cancer.

SOR-C13 targets TRPV6, a calcium channel prevalent in prostate, breast, lung and ovarian cancer.